These results suggest that ALK activates downstream signaling molecules in parallel with the conventional SHH pathway, and opens the possibility of using ALK inhibitors, perhaps in combination with vismodegib, in the treatment of BCC. Here, SHH is linked to skin basal cell carcinoma.